NFKB1 and neoplasm: Studies targeting the nuclear factor kappa B (NF-kB) pathway, activated by RAL, have demonstrated that KRAS-mutant tumor cells require NF-kB for viability [76] and inhibitors targeting this effector are also being tested in clinical trials [77].